RA Capital Healthcare Fund LP's Form 4 filing
Parabilis Medicines, Inc. (PBLS) · filed Jun 15, 2026
- Accession no.
- 0001231919-26-000638
- Filed
- Jun 15, 2026, 6:57 PM ET
- Trade date
- Jun 11, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market purchases total $423.8M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Voting Common Stock | CConversionAcquired | +6,556,740 | –F1,F2 | – | 6,556,740 | Indirect | |
| Jun 11, 2026 | Voting Common Stock | CConversionAcquired | +1,187,881 | –F1,F2 | – | 1,187,881 | Indirect | |
| Jun 11, 2026 | Voting Common Stock | PPurchaseAcquired | +19,728,353 | $20.00 | +$394,567,060 | 26,285,093 | Indirect | |
| Jun 11, 2026 | Voting Common Stock | PPurchaseAcquired | +1,460,397 | $20.00 | +$29,207,940 | 2,648,278 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Voting Common Stock | CConversionDisposed | −419,006 | –F1 | – | 0 | Indirect | |
| Jun 11, 2026 | Voting Common Stock | CConversionDisposed | −104,751 | –F1 | – | 0 | Indirect | |
| Jun 11, 2026 | Voting Common Stock | CConversionDisposed | −6,137,734 | –F2 | – | 0 | Indirect | |
| Jun 11, 2026 | Voting Common Stock | CConversionDisposed | −1,083,130 | –F2 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series E Preferred Stock automatically converted into Voting Common Stock on a 1 to 0.6524 basis immediately prior to the closing of the IPO and without payment of consideration. The Series E Preferred Stock has no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
- F2
Each share of Series F Preferred Stock automatically converted into shares of Voting Common Stock on a 1 to 0.6498 basis immediately prior to the closing of the IPO and without payment of consideration. The Series F Preferred Stock has no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
Remarks
Dr. Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.